Results 191 to 200 of about 262,647 (304)

Physiologically‐based pharmacokinetic modelling of uridine 5′‐diphosphoglucorosultransferase (UGT) substrate drugs in pregnant women

British Journal of Clinical Pharmacology, EarlyView.
Aims While pregnancy‐related changes in phase I enzyme activity are well‐documented, less is known about the impact on phase II enzymes. This study aimed to test the hypothesis that changes in the pharmacokinetics (PK) of uridine 5′‐diphosphoglucuronosyltransferase (UGT) substrates during pregnancy result from altered enzyme expression or activity ...
William Saffaf, Ymke van der Velde, Paul R. V. Malik, Jelmer R. Prins, Sanne J. Gordijn, Daan J. Touw, Paola Mian   +6 more
wiley   +1 more source

Sex-Dependent Effects of Rivastigmine on Melatonin Receptors in Middle-Aged Rats. [PDF]

Noro Psikiyatr Ars
Ünal NA, Ak ET, Ünal Ö, Ağar E, Ayyıldız M.   +4 more
europepmc   +1 more source

PrEP at the site of action in cisgender and transgender women: A pharmacology study of blood and rectal CD4+ lymphocytes

British Journal of Clinical Pharmacology, EarlyView.
Background Female sex hormones used in feminizing hormone therapy (FHT) may influence activation and persistence of HIV pre‐exposure prophylaxis (PrEP) medications. The clinical relevance of this interaction remains unclear, particularly for transgender and cisgender women (TGW and CGW).
Elizabeth Hastie, Megha Srivasta, Edward R. Cachay, Leah Burke, Sara Gianella, Stephen Rawlings, Frank Z. Stanczyk, Craig Sykes, Angela D. M. Kashuba, Jill Blumenthal, Mackenzie L. Cottrell   +10 more
wiley   +1 more source

Estrogenic control of germ cell differentiation in medaka: independence of early sex dimorphism from zygotic estrogen and receptor signaling. [PDF]

Front Endocrinol (Lausanne)
Sakai-Yamada Y, Myosho T, Kayo D, Kanda S, Kobayashi T.   +4 more
europepmc   +1 more source

Endogenous melatonin partial metabolic clearance as a potential endogenous marker of CYP1A2 activity

British Journal of Clinical Pharmacology, EarlyView.
Aims Cytochrome P450 1A2 (CYP1A2) exhibits substantial interindividual variability, necessitating appropriate phenotyping strategies for personalized pharmacotherapy. This study evaluated endogenous melatonin partial metabolic clearance (CLm(MEL)), calculated from urinary 6‐hydroxymelatonin (6‐O‐MEL) excretion and plasma melatonin (MEL) exposure, as a ...
Akitomo Yokokawa, Hayato Shimazaki, Shunji Igarashi, Yoshiki Tagawa, Naoki Hisada, Hiromi Shibasaki   +5 more
wiley   +1 more source

The triangular drivers of bone aging: mechanistic insights and therapeutic targets in cellular senescence, estrogen deficiency, and gut microenvironment dysregulation. [PDF]

Front Cell Dev Biol
Liu Z, Peng Y, Hou J, Zhang G, Wang J.
europepmc   +1 more source

Selective estrogen receptor modifiers on the antidepressant-like effects of electroconvulsive seizures in adolescent rats. [PDF]

Transl Psychiatry
Garau C, Ledesma-Corvi S, Jiménez-Marín Y, García-Cabrerizo R, García-Fuster MJ.   +4 more
europepmc   +1 more source

Estrogen Receptors

Journal of Biological Chemistry, 1971
George Giannopoulos, Jack Gorski
openaire   +1 more source

Effects of antialdosteronics on plasmatic hormonal levels and an hepatic sexual steroid receptors in rat [PDF]

, 1987
Aguilino, AM, Barone, M, DiLeo, A, Eagon, PK, Fanizza, G, Ferrara, R, Francavilla, A, Giangaspero, A, Guglielmi, FW, Polimeno, L, Starzl, TE, Zizza, G   +11 more
core  

Reprogramming tumor immune microenvironment by ultrasound‐responsive nanoplatforms for enhanced cancer immunotherapy

BMEMat, EarlyView.
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao, Rui Qu, Zan Dai, Xiqun Jiang, Xu Zhen   +4 more
wiley   +1 more source